Page 167 - 2019_11 Resto del Mondo-web

Phase II CARTHADEX Study in NDMM
Lancet Oncol. 2016;17(1):27-38.
11. Sonneveld P, Asselbergs E, Zweegman S, et al. Phase 2 study of carfilzomib, thalido- mide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood. 2015;
125(3):449-456.
12. Jakubowiak AJ, Dytfeld D, Griffith KA, et
al. A phase 1/2 study of carfilzomib in com- bination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9): 1801-1809.
13. Mikhael JR, Reeder CB, Libby EN, et al. Phase Ib/II trial of CYKLONE (cyclophos- phamide, carfilzomib, thalidomide and dex- amethasone) for newly diagnosed myelo- ma. Br J Haematol. 2015;169(2):219-227.
14. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dex- amethasone in patients with newly diag- nosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63-69.
15. Moreau P, Kolb B, Attal M, et al. Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood. 2015;125(20):3100-3104.
16. Papadopoulos KP, Siegel DS, Vesole DH, et
al. Phase I study of 30-minute infusion of carfilzomib as single agent or in combina- tion with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol. 2015; 33(7):732-739.
17. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):933-939
18. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328- e346.
19. Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015; 1(8):1051-1059.
20. Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfil- zomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised,
phase 3 study. Lancet Oncol. 2018;
19(7):953-964.
21. Goldschmidt H, Lokhorst HM, Mai EK, et
al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018;32(2):383-390.
22. Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dex- amethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014;32(25):2712-2717.
23. Sonneveld P, Juni 2018. Consolidation fol- lowed by maintenance vs. maintenance alone in newly diagnosed, transplant eligi- ble multiple myeloma: a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM TRIAL). Abstract presented at the EHA meeting, Stockholm, Sweden. Abstract retrieved from https://learningcenter.ehaweb.org/ eha/2018/stockholm/214488/pieter.sonn- eveld.consolidation.followed.by.mainte- nance.vs.maintenance.alone.in.html. Abstract # S108.
haematologica | 2019; 104(11)
2273